2月4日，心泰医疗(02291)盘中上涨5.6%，截至13:44，报18.48元/股，成交154.34万元。
乐普心泰医疗科技(上海)股份有限公司主营业务为结构性心脏病医疗介入器械的研发、生产和营销，是中国首屈一指的先天性心脏病封堵器械提供商，具有多样的产品线为结构性心脏病介入治疗提供全面解决方案。至2023年4月26日，公司拥有已注册知识产权234项，产品已销售至50个国家和地区，包括亚洲、欧洲、美洲和非洲。
截至2024年中报，心泰医疗营业总收入2.49亿元、净利润1.4亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.